Calcipotriol: Indication, Dosage, Side Effect, Precaution

Generic Medicine Info Patient Medicine Information

This information is not country-specific. Please refer to the Malaysia prescribing information.

Generic Medicine Info

Indications and Dosage

Topical/Cutaneous
Mild to moderate plaque psoriasis

Adult: As 0.005% cream/oint: Apply a thin layer and rub in gently and completely to the affected area 1-2 times daily. Max: 100 g/wk; if used together w/ scalp soln, 5 mg of the drug per wk (e.g. cream/oint 60 g w/ scalp soln 40 mL or cream/oint 40 g w/ scalp soln 60 mL).
Child: As 0.005% oint: Apply bid. Max: 6-12 yr 50 g/wk; >12 yr 75 g/wk. Max duration: 8 wk.

Topical/Cutaneous
Scalp psoriasis

Adult: As 0.005% soln: Apply and rub in gently and completely to the affected area bid. Avoid contact w/ the forehead or uninvolved scalp margin. Max: 60 mL/wk; if used together w/ cream/oint, 5 mg of the drug per wk (e.g. cream/oint 60 g w/ scalp soln 40 mL or cream/oint 40 g w/ scalp soln 60 mL).

Renal Impairment

Severe: Contraindicated.

Hepatic Impairment

Severe: Contraindicated.

Contraindications

Hypercalcaemia, Ca metabolism disorder. Acute psoriatic eruptions (scalp soln). Severe renal or hepatic impairment.

Special Precautions

Patient w/ erythrodermic exfoliative psoriasis, generalised pustular psoriasis. Pregnancy and lactation.

Adverse Reactions

Skin irritation, burning, itching, erythema, and dryness; eczema, contact dermatitis, aggravated psoriasis; hypercalcaemia, hypercalciruria. Rarely, skin atrophy, hyperpigmentation, photosensitivity.

Pregnancy Category (US FDA)

Topical: C

Patient Counseling Information

Avoid application to the face, eyes, or mucous membranes. Avoid exposure to natural or artificial sunlight.

Monitoring Parameters

Monitor serum Ca.

Drug Interactions

Inactivated by salicylic acid externals.

Action

Description:
Mechanism of Action: Calcipotriol, a synthetic vit D₃ derivative, is an antipsoriatic agent. It binds to vit D receptors to induce differentiation and supress proliferation of keratinocytes.
Onset: 2 wk; marked improvement seen after 8 wk.
Pharmacokinetics:
Absorption: <1% is absorbed when applied to psoriasis plaques (soln); approx 6% is absorbed (oint).
Metabolism: Rapidly metabolised into inactive metabolites.

Chemical Structure

Storage

Store between 15-25°C. Do not freeze. Soln: Keep away from sunlight or open flame.

MIMS Class

Psoriasis, Seborrhea & Ichthyosis Preparations

ATC Classification

D05AX02 - calcipotriol ; Belongs to the class of other antipsoriatics for topical use.

References

Anon. Calcipotriene. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 08/11/2016.

Buckingham R (ed). Calcipotriol. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 08/11/2016.

Calcipotriene Cream (Sandoz Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 08/11/2016.

Calcipotriene Ointment (Prasco Laboratories). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 08/11/2016.

Calcipotriene Solution (Impax Generics). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 08/11/2016.

Joint Formulary Committee. Calcipotriol. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 08/11/2016.

Leo Pharma Ltd. Daivonex Ointment data sheet January 2016. Medsafe. http://www.medsafe.govt.nz/. Accessed 10/11/2016.

McEvoy GK, Snow EK, Miller J et al (eds). Calcipotriene (Topical). AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 08/11/2016.

Disclaimer: This information is independently developed by MIMS based on Calcipotriol from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by MIMS.com